tiprankstipranks
Advertisement
Advertisement
Voyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
PremiumRatingsVoyager Therapeutics: Differentiated CNS Platform, Strategic Partnerships, and 2026 Data Catalysts Underpin Buy Rating
2M ago
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
Premium
Ratings
Voyager Therapeutics: Advancing Tau-Targeted Gene Therapy with Multiple Near-Term Catalysts and Attractive Risk-Reward
2M ago
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships
Premium
Company Announcements
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships
2M ago
Voyager Therapeutics Announces Chief Medical Officer Resignation
PremiumCompany AnnouncementsVoyager Therapeutics Announces Chief Medical Officer Resignation
3M ago
Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy
Premium
Company Announcements
Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy
4M ago
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
Premium
The Fly
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
6M ago
Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)
PremiumThe FlyVoyager Therapeutics reports Q3 EPS (47c), consensus (52c)
6M ago
Voyager Therapeutics expects cash to fund operations into 2028
Premium
The Fly
Voyager Therapeutics expects cash to fund operations into 2028
6M ago
Voyager Therapeutics, Transition Bio entered into drug discovery collab
Premium
The Fly
Voyager Therapeutics, Transition Bio entered into drug discovery collab
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100